ImmuPharma (LON:IMM) Shares Up 30.2% - Here's What Happened

Key Points

• ImmuPharma's shares surged by 30.2% during mid-day trading, reaching a high of GBX 19.35 ($0.26), with a notable trading volume increase of 365% from its average.
• The company reported a negative earnings per share of GBX (0.38) for the previous quarter, and analysts predict a projected EPS of -339.00 for the current fiscal year.
• ImmuPharma specializes in developing peptide-based therapeutics for autoimmune diseases, with its lead program, P140 (Lupuzor™), targeting the treatment of Lupus.

ImmuPharma plc (LON:IMM - Get Free Report) shares shot up 30.2% during mid-day trading on Monday . The stock traded as high as GBX 19.35 ($0.26) and last traded at GBX 18.20 ($0.25). 38,553,926 shares traded hands during trading, an increase of 365% from the average session volume of 8,294,800 shares. The stock had previously closed at GBX 13.98 ($0.19).

ImmuPharma Price Performance

The firm's fifty day moving average price is GBX 3.12 and its 200-day moving average price is GBX 2.91. The company has a market cap of £90.95 million, a price-to-earnings ratio of -2,044.94 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, equities analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.